CS
NAGE

Credit Suisse’s Niagen Bioscience NAGE Stock Holding History

Credit Suisse’s Portfolio NAGE Stock Details NAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-25
Closed – – 4354
2022
Q2 		$0 Buy
+25
New +$49 ﹤0.01% 4393
2021
Q1 		– Sell
-13,147
Closed -$63K – 4614
2020
Q4 		$63K Buy
+13,147
New +$64.1K ﹤0.01% 4229
2018
Q3 		– Sell
-12,840
Closed -$48K – 4034
2018
Q2 		$48K Buy
+12,840
New +$48.8K ﹤0.01% 3906
2018
Q1 		– Sell
-16,518
Closed -$97K – 4181
2017
Q4 		$97K Buy
+16,518
New +$89.2K ﹤0.01% 3843
2017
Q3 		– Sell
-55,381
Closed -$211K – 4276
2017
Q2 		$211K Buy
+55,381
New +$175K ﹤0.01% 3606
2017
Q1 		– Sell
-11,271
Closed -$37K – 4113
2016
Q4 		$37K Sell
11,271
-111
-1% -$302 ﹤0.01% 4044
2016
Q3 		$34K Sell
11,382
-740
-6% -$2.72K ﹤0.01% 4043
2016
Q2 		$50K Buy
+12,122
New +$57.3K ﹤0.01% 4150

Other funds holding NAGE

TCM
Tieton Capital Management Yakima, Washington $299M AUM 54.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
YRHAM
Yong Rong (HK) Asset Management Sheung Wan, Hong Kong $227M AUM 300.38% 1-Year Est. Return
IC
Iconiq Capital San Francisco, California $4.46B AUM 22.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Credit Suisse's NAGE Position: Q3 2022 in Review

Credit Suisse sold out of Niagen Bioscience (NAGE) in Q3 2022, closing a stake of 25 shares.

Credit Suisse first reported a position in NAGE in Q2 2016 and held it in 8 quarters. The position peaked at $211K in Q2 2017. 62 funds tracked by Wall St. Rank hold NAGE as of Q3 2022.

  • Credit Suisse reported no remaining Niagen Bioscience position as of Q3 2022 after selling out during the quarter.
  • Credit Suisse sold 25 Niagen Bioscience shares in Q3 2022.
  • Credit Suisse first reported a position in Niagen Bioscience in Q2 2016 and held it in 8 quarters.
  • Credit Suisse's Niagen Bioscience position peaked at $211K in Q2 2017.
  • 62 funds tracked by Wall St. Rank held Niagen Bioscience as of Q3 2022.

Based on Credit Suisse's 13F filing for Q3 2022, filed 10 Nov 2022.